Regulus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Updates
Portfolio Pulse from
Regulus Therapeutics reported positive interim results from a Phase 1b trial of farabursen for ADPKD and reached an agreement with the FDA on a Phase 3 trial for potential Accelerated Approval.
March 13, 2025 | 8:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Regulus Therapeutics announced positive interim results from a Phase 1b trial of farabursen for ADPKD and an agreement with the FDA on a Phase 3 trial for potential Accelerated Approval.
The positive interim results from the Phase 1b trial and the agreement with the FDA on a Phase 3 trial for potential Accelerated Approval are significant milestones for Regulus Therapeutics. These developments could lead to increased investor confidence and a potential rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100